CorConsult Rx: Evidence-Based Medicine and Pharmacy · Mike Corvino, PharmD, BCPS, BCACP, CDE and Cole Swanson, PharmD

Alteplase vs Tenecteplase for Ischemic Stroke

·1 hr 1 min·5 clips

Dr. Brian Gilbert returns to discuss alteplase vs tenecteplase after joking about stealing the show.

This episode of CorConsult Rx focuses on the clinical evidence comparing alteplase and tenecteplase for the treatment of acute ischemic stroke. Host Ben welcomes returning guest Dr. Brian Gilbert, a critical care pharmacy specialist and residency program director. Dr. Gilbert's expertise in emergency medicine and critical care pharmacotherapy grounds the discussion in practical, frontline experience. The conversation centers on the evolution of tenecteplase from a cardiac agent to a potential stroke thrombolytic. They reference key trials like EXTEND-IA TNK and NOR-TEST that investigated tenecteplase in stroke. Dr. Gilbert explains the pharmacological advantages of tenecteplase, including its longer half-life and single bolus administration. He details how these properties can simplify pharmacy workflows and reduce door-to-needle times in the emergency department. The hosts compare the molecular structures of the two agents, specifically the T103N and N117Q mutations in tenecteplase. They discuss real-world implementation challenges, such as updating hospital protocols and educating nursing staff. The episode also touches on cost considerations and formulary management for health systems adopting tenecteplase. A compelling insight is that tenecteplase may offer non-inferior efficacy with a potentially improved safety profile regarding intracranial hemorrhage. Dr. Gilbert notes the significant operational benefit of a single bolus dose, which eliminates the need for a complex infusion pump setup. He describes the practical scenario of preparing and administering the drug during a stroke code. The discussion highlights how tenecteplase use could expedite subsequent procedures like thrombectomy. They acknowledge that current guidelines still position tenecteplase as an alternative, not a wholesale replacement, for alteplase. Dr. Gilbert provides a nuanced view on patient selection, suggesting tenecteplase might be particularly advantageous in specific clinical situations. The tone is highly conversational and collegial, marked by friendly banter between the host and guest. The style is educational and clinically focused, translating trial data into actionable practice insights for pharmacists. Hospital and critical care pharmacists managing stroke protocols would find this episode immediately applicable. Listeners seeking a broad, patient-facing health podcast or a debate on fundamental stroke pathophysiology might find the technical, pharmacy-centric discussion too specialized.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from CorConsult Rx: Evidence-Based Medicine and Pharmacy